Smith-Cohn Matthew A, Celiku Orieta, Gilbert Mark R
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1016, Bethesda, MD 20892, USA; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1142, Bethesda, MD 20892, USA.
Neurosurg Clin N Am. 2021 Apr;32(2):191-210. doi: 10.1016/j.nec.2020.12.002. Epub 2021 Feb 18.
Glioblastoma remains incurable despite advances in surgery, radiation, and chemotherapy, underscoring the need for new therapies. The genetic heterogenicity, presence of redundant molecular pathways, and the blood-brain barrier have limited the applicability of molecularly targeted agents. The therapeutic benefit seen with a small subset of patients suggests, however, that patient selection is critical. Recent investigations show that molecularly targeted synthetic lethality is a promising complementary approach. The article provides an overview of the challenges of molecularly targeted therapy in adults with glioblastoma, including current trials and future therapeutic directions.
尽管在手术、放疗和化疗方面取得了进展，但胶质母细胞瘤仍然无法治愈，这突出表明需要新的治疗方法。基因异质性、冗余分子通路的存在以及血脑屏障限制了分子靶向药物的适用性。然而，一小部分患者所显示的治疗益处表明，患者选择至关重要。最近的研究表明，分子靶向合成致死是一种有前景的补充方法。本文概述了成人胶质母细胞瘤分子靶向治疗面临的挑战，包括当前的试验和未来的治疗方向。
